Opportunity Alert – AC-160105-085 – TAKEDA-05
Date Sourced: March 8, 2016
Category: Customer Opportunity
Status: Qualifying
Potential (High-Moderate-Low): Moderate
Add to SFA (Y/N): TBD
Client Action Required (Y/N): No
Opportunity:
Takeda Pharmaceutical is among the top 15 pharmaceutical companies in the
United States with global clinical trial operations. They have a robust
pipeline of compounds in multiple therapeutic areas including: metabolic
and cardiovascular diseases, central nervous system, respiratory and
immunology, oncology and general medicine.
Website: www.takeda.us
Summary of Activities/Tasks:
1. March 8, 1016 – Contacted Atul Mahableshwarkar, Senior Medical Director
Takeda Pharmaceuticals.
2. March 10, 2016 – Spoke with Atul at length regarding CleverCap and med
adherence efforts at Takeda. He sees current compliance efforts at Takeda
as “inadequate.” Says that it is a huge issue; and that he would consider
CleverCap as being very valuable. Only significant question was, “How does
CleverCap compare to MEMcaps from an outcomes/impact standpoint?” Atul
co-chairs the med adherence committee at Takeda. Works from Chicago
location.
3. March 17, 2016 – Sent Atul the CleverCap short deck and asked for input
on upcoming trials where we could potentially pilot CleverCap.
4. March 25, 2016 – Reached out to follow-up with Atul. Looking to
coordinate an in-person meeting in Chicago. Aims are to: (a) provide a
short technology demo and (b) talk through how CleverCap could deliver
improved clinical trial data quality, cost savings, and subject compliance
and retention for Takeda. Looking to meet btwn 4/19-4/21.
Forward Statements and Guidance:
Patriot Labs has several stakeholder contacts within Takeda that can be
pursued, including Ryan McClellan and Mike Abbadessa as covered within
opportunity alert TAKEDA-01. Additional updates to follow leading up to,
and after the April 19-21 meetings.
End.
Return to Listing
COMMENT FORM.
Comments
Facilitator
Atul R. Mahablesh MD, DFAPA
Senior Medical Director
Takeda Development Center Americas, Inc.
Atul is co-chairing a session on compliance issues in CNS Clinical trials at the upcoming ASCP meeting in Scottsdale, AZ. He will be presenting CleverCap as a recommended technology to ensure compliance.